| Basics |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
|
| IPO Date: |
May 28, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$60.52B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.73 | 2.19%
|
| Avg Daily Range (30 D): |
$7.22 | 1.60%
|
| Avg Daily Range (90 D): |
$6.92 | 1.57%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.55M |
| Avg Daily Volume (30 D): |
.84M |
| Avg Daily Volume (90 D): |
.93M |
| Trade Size |
| Avg Trade Size (Sh.): |
77 |
| Avg Trade Size (Sh.) (30 D): |
26 |
| Avg Trade Size (Sh.) (90 D): |
33 |
| Institutional Trades |
| Total Inst.Trades: |
10,616 |
| Avg Inst. Trade: |
$7.19M |
| Avg Inst. Trade (30 D): |
$35.53M |
| Avg Inst. Trade (90 D): |
$32.08M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$12.82M |
| Avg Closing Trade (30 D): |
$59.32M |
| Avg Closing Trade (90 D): |
$62.8M |
| Avg Closing Volume: |
82.17K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$.33
|
$1.91
|
$-.51
|
|
Diluted EPS
|
$.3
|
$1.84
|
$-.51
|
|
Revenue
|
$ 3.21B
|
$ 1.25B
|
$ 773.69M
|
|
Gross Profit
|
$ 2.7B
|
$ 1.05B
|
$ 631.66M
|
|
Net Income / Loss
|
$ 43.57M
|
$ 251.08M
|
$ -66.28M
|
|
Operating Income / Loss
|
$ 264.7M
|
$ 367.98M
|
$ -16.2M
|
|
Cost of Revenue
|
$ 512.09M
|
$ 197.23M
|
$ 142.03M
|
|
Net Cash Flow
|
$ 390.3M
|
$ 376.94M
|
$ 93.61M
|
|
PE Ratio
|
1,441.02
|
|
|
|
|
|
